Estados Unidos · Revistas de economía · Inc.

This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent

Publicado por Inc. · Estados Unidos hace 2 h

A groundbreaking phase 3 clinical trial reveals that a personalized mRNA vaccine from Merck and Moderna significantly cuts the risk of melanoma returning.

Leer el artículo completo en Inc. Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.inc.com)

This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent

También te puede interesar

12 things to do in Istanbul, from Hagia Sophia to a Bosphorus ferry

A $44 million superhero horror film won the box office this weekend. A $7 million documentary came within $5 million of beating it

Stocks Start a Big Week With Solid Gains: Stock Market Today

Microsoft offers voluntary buyouts to 60,000 employees as tech giant reshapes its workforce

Entrepreneurship might be the key to a longer life

Megan Thee Stallion Says This Is the ‘Biggest Mistake’ She Made Early in Her Career — And How She Fixed It

This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent

Compartir

También te puede interesar

12 things to do in Istanbul, from Hagia Sophia to a Bosphorus ferry

A $44 million superhero horror film won the box office this weekend. A $7 million documentary came within $5 million of beating it

Stocks Start a Big Week With Solid Gains: Stock Market Today

Microsoft offers voluntary buyouts to 60,000 employees as tech giant reshapes its workforce

Entrepreneurship might be the key to a longer life

Megan Thee Stallion Says This Is the ‘Biggest Mistake’ She Made Early in Her Career — And How She Fixed It